The global bispecific antibody market size was USD 1.50 Bn in 2022 and is likely to reach USD 4.32 Bn by 2031, expanding at a CAGR of 10% during 2023–2031. The market growth is attributed to the distinguishing ability of bispecific antibodies (bsAb) in managing chronic diseases effectively and technological advancements in bispecific antibody therapeutics.
Bispecific antibodies are a type of artificial protein that can bind two separate and unique antigens to treat complex and multifaceted diseases. These antibodies use a multi-targeting approach to treat multi-factorial diseases for safe and effective treatment. They are used to treat a wide range of diseases such as autoimmune disorders, cardiovascular diseases, infectious diseases, and the rejection of organ transplants.
Various pharmaceutical companies are forming strategic alliances to formulate promising prospects in bispecific antibodies. Increasing clinical trials are being conducted in an effort to study the specificity, penetration power, and target ability of antigens precisely targeting different types of ailments. This development in the pharmaceutical sector is increasing the demand for bispecific antibodies.
COVID-19 Impact on Bispecific Antibody Market
The market report finds that the COVID-19 pandemic had delayed clinical research and the consecutive launch of new antibody therapies. The change of focus of healthcare human resources toward the COVID-19 cure research is the major reason for this delay. The supply chain disruption in the raw materials required for the production of bispecific antibodies also affected the market during the peak of the pandemic.
Global Bispecific Antibody Market Dynamics
The global bispecific antibody market report has up-to-date insights that help in formulating a strategic roadmap about the estimated market scenario and performance during 2023 to 2031.
What are the Major Factors Driving the Growth of the Bispecific Antibody Market?
Bispecific antibodies have been receiving recognition from regulatory bodies as a viable method of treating complex diseases, which is expected to fuel the market growth during the projection period. This rise in demand stemmed from the fact that specific diseases needed to be treated with certain sets of methods and medications to avoid complications.
Bispecific antibodies are widely accepted among clinicians and patients as an effective treatment method because of their target-specific treatment capability. Bispecific antibodies are preferred over bispecific monoclonal antibodies (BsMAb) because of their improved ability to target disease-specific molecules and better efficacy.
Bispecific antibodies are preferred as they can facilitate highly selective interactions between molecules on the surface of cancer cells and cells in the immune system. These characteristics of antibodies for selective interaction minimize the side effects arising out of the treatment. These wide advantages offered by bispecific antibodies over traditional antibodies in the treatment of various serious diseases are expected to drive market growth during the forecast period.
What Restraints the Bispecific Antibody Market?
The lack of funds for research and development in adverse scenarios can hamper the growth of the market. Volatile market conditions because of economic slowdown and its associated ripple effects in fund allocations for research and development of bispecific antibodies is anticipated to limit the market growth.
What are the Opportunities in the Bispecific Antibody Market?
Major organizations in the market are achieving phenomenal success with the launching of next-generation bispecific antibodies for the management of chronic ailments such as Cancer and Alzheimer’s disease. The ability of bispecific antibodies to manage chronic ailments in a short span of time has encouraged several pharmaceutical companies to raise investments in research and development.
The advancements in the sector are characterized by investments raised for research and development. Pharmaceutical organizations in the market are anticipated to witness significant growth by launching new therapies in the future creating significant opportunities for market growth.
Scope of the Bispecific Antibody Market Report
The global bispecific antibody market research report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Bispecific Antibody Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2020–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Type (Non-Immunoglobulin G Like Molecule and Immunoglobulin G Like Molecule), Application (Autoimmune Disease, Cancer, and Others), Mechanism of Action (Bispecific T-Cell Engager Antibodies, and Bispecific Diabodies), Drug Type (Catumaxomab, Blinatumomab, Duligotumab, and Other Drugs), Route of Administration (Injectable and Oral), End-user (Specialty Clinics, Hospitals, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Adimab, LLC; AstraZeneca; Baxter; Dow; GSK plc.; Sanofi ; F. Hoffmann-La Roche Ltd; Regeneron Pharmaceuticals Inc.; Pfizer Inc.; Johnson & Johnson Services Inc.; Novartis AG and CELGENE CORPORATION
|
Global Bispecific Antibody Market Segment Insights
What Factors Attributes to the Growth of the Immunoglobulin G Like Molecules Segment?
On the basis of type, the global bispecific antibody market is bifurcated into Non-immunoglobulin G (IgG) like molecules and Immunoglobulin G (IgG) like molecules.
The Immunoglobulin G (IgG) like molecules segment is projected to register a considerable CAGR during the forecast period owing to its promising therapeutic properties in autoimmune diseases and cancer immunotherapy. The segment growth is further attributed to advances in genetic engineering technology to build better antibodies for improved efficacy.
Which Factors Drive the Cancer Segment Growth?
Based on application, the global bispecific antibody market is segmented into autoimmune disease, cancer, and others.
The cancer segment is expected to expand at a significant growth rate during the projection period owing to the perfect modality and penetration power of bispecific antibodies in the treatment of various cancer types including lymphoma treatment. The segment growth is further signified by the exceptional characteristics of bispecific antibodies to maximize therapeutic effects.
The autoimmune disease segment is anticipated to hold a key share of the market in the coming years due to the rise in autoimmune diseases across the world. The bispecific antibodies can boost immune response in treating autoimmune diseases by specifically targeting the disease-related molecules.
What Factors Influence the Growth of the Bispecific T-Cell Engager Antibodies Segment?
On the basis of the mechanism of action segment, the global bispecific antibody market is segmented into bispecific T-Cell engager antibodies and bispecific diabodies.
The bispecific T-Cell engager antibodies segment is expected to register a robust growth rate during the forecast period owing to its ability to enhance the patient’s immune system by directing T-cell’s cytotoxic activity. These antibodies direct the immune system of the host against cancerous cells.
What Factors Drive the Blinatumomab Drug Type Segment Growth?
Based on the drug type segment, the global bispecific antibody market is segmented into catumaxomab, blinatumomab, duligotumab, and others.
The blinatumomab segment is projected to register a considerable CAGR during the forecast period owing to its ability to direct the human immune system to act against tumor cells selectively. The high acceptance rate for blinatumomab among clinicians is driving the market growth of this segment.
Which Factors Constitute Injectable Segment Growth in the Bispecific Antibody Market?
Based on the route of administration segment, the global bispecific antibody market is bifurcated into injectable and oral.
The injectable segment is projected to register a considerable CAGR during the forecast period owing to its efficacy and rate of recovery after the administration of the antibodies. The segment growth is further attributed to the rising use of injectables bispecific antibodies for achieving fast results.
What Factors Facilitate Hospitals Segment Growth in the Market?
Based on the end-user segment, the global bispecific antibody market is categorized into specialty clinics, hospitals, and others.
The hospitals segment is projected to register a considerable CAGR during the forecast period owing to the ease of availing and administering the antibodies at the hospitals. The patients tend to get the drugs injected at the hospitals. This factor may contribute to the growth of the hospital segment significantly.
What Factors Lead to the Growth of Hospital Pharmacies Segment?
On the basis of the distribution channel segment, the global market is segregated into retail pharmacies, online pharmacies, and hospital pharmacies.
The hospital pharmacies segment is projected to register a considerable CAGR during the forecast period owing to the over-the-counter availability of bispecific antibody drugs at the hospitals. The convenience of availing the bispecific antibodies drugs readily at the hospitals is significantly contributing to the market growth.
Why is North America Dominating the Bispecific Antibody Market?
In terms of region, the global bispecific antibody market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.
North America is expected to dominate the market during the projection period as a result of supportive government policies and the high prevalence of chronic diseases. The growth in the segment is also characterized by the development of innovative bispecific antibody products and the high expenditure power of patients.
Asia-Pacific is expected to grow rapidly in the global market during the projection period as a result of increased spending by government bodies on novel treatment methods, a high patient pool, and the high reliability of antibody treatments in the region. The market growth is also influenced by government initiatives in the region to promote novel therapies for the safe and target-specific treatment of multifaceted diseases.
Segments
The global bispecific antibody market has been segmented on the basis of
Type
- Non-Immunoglobulin G Like Molecules
- Immunoglobulin G Like Molecules
Application
- Autoimmune Disease
- Cancer
- Others
Mechanism of Action
- Bispecific T-Cell Engager Antibodies
- Bispecific Diabodies
Drug Type
- Catumaxomab
- Blinatumomab
- Duligotumab
- Others
Route of Administration
End-user
- Specialty Clinics
- Hospitals
- Others
Distribution Channel
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Adimab LLC.
- AstraZeneca
- Baxter
- Dow
- GSK plc.
- Sanofi
- F. Hoffmann-La Roche Ltd.
- Regeneron Pharmaceuticals Inc.
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Novartis AG
- CELGENE CORPORATION[VG1]
Competitive Landscape
Key players competing in the market are Adimab, LLC; AstraZeneca; Baxter; Dow; GSK plc.; Sanofi ; F. Hoffmann-La Roche Ltd; Regeneron Pharmaceuticals Inc.; Pfizer Inc.; Johnson & Johnson Services Inc.; Novartis AG and CELGENE CORPORATION. Some of these major companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide.
- On January 11, 2023, Adimab LLC announced that it has entered into the clinical development of bispecific antibodies in seven new partner programs with various partners including Biotheus, Dragonfly, Innovent, and Surface Oncology.
- On December 10, 2022, Johnson & Johnson Services, Inc. announced the results of a talquetamab, a bispecific T-cell engager antibody that could trigger the human body’s system to fight blood cancer.
Request For Customization
Enquiry Before Buying
Speak With Analyst
